PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

More search options...

McCormack, S; Ramjee, G; Kamali, A; Rees, H; Crook, AM; Gafos, M; Jentsch, U; Pool, R; Chisembele, M; Kapiga, S; Mutemwa, R; Vallely, A; Palanee, T; Sookrajh, Y; Lacey, CJ; Darbyshire, J; Grosskurth, H; Profy, A; Nunn, A; Hayes, R; Weber, J; (2010) PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet, 376 (9749). pp. 1329-37. ISSN 0140-6736 DOI: 10.1016/S0140-6736(10)61086-0

Preview

PDF - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.
Download (545Kb) | Preview

Abstract

Innovative prevention strategies for HIV-1 transmission are urgently needed. PRO2000 vaginal gel was efficacious against HIV-1 transmission in studies in macaques; we aimed to assess efficacy and safety of 2% and 0·5% PRO2000 gels against vaginal HIV-1 transmission in women in sub-Saharan Africa.

Item Type:	Article
Faculty and Department:	Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology Faculty of Public Health and Policy > Dept of Global Health and Development Faculty of Epidemiology and Population Health > Dept of Population Health (2012- ) > Dept of Population Studies (1974-2012) Faculty of Epidemiology and Population Health > Dept of Population Health (2012- )
Research Centre:	Tropical Epidemiology Group
PubMed ID:	20851460
Web of Science ID:	283528600035
URI:	http://researchonline.lshtm.ac.uk/id/eprint/2836

Statistics

Item downloaded times since 17 Oct 2011 15:06.

View statistics for "PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial."

Actions (login required)

Edit Item